Fulgent Genetics (FLGT) FDA Approvals $18.18 +0.34 (+1.91%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$17.85 -0.33 (-1.81%) As of 04:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Fulgent Genetics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Fulgent Genetics (FLGT). Over the past two years, Fulgent Genetics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as FID-007. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. FID-007 FDA Regulatory Events FID-007 is a drug developed by Fulgent Genetics for the following indication: 2nd line treatment of patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Abstract - May 21,2026Abstract Drug: FID-007Announced Date: May 21, 2026Indication: 2nd line treatment of patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).AnnouncementFulgent Genetics, Inc announced that its full abstract has been released on the ASCO 2026 website.AI SummaryFulgent Genetics, Inc. said its full abstract is now available on the ASCO 2026 website. The release gives investors and researchers a closer look at the company’s latest oncology-related findings. The abstract highlights key observations from the study, showing the main results and early data that Fulgent wants to share with the medical community. This update matters because ASCO is one of the most important cancer research meetings in the world. Having the full abstract posted online allows doctors, scientists, and investors to review the details ahead of the conference. Fulgent said the information reflects its ongoing work in precision medicine and cancer testing, and it may help guide future research and product development. The company also included standard forward-looking statement language and investor contact information in the announcement.Read AnnouncementPreclinical Data - October 20,2025Preclinical Data Drug: FID-007Announced Date: October 20, 2025Indication: 2nd line treatment of patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).AnnouncementFulgent Genetics, Inc. announced preliminary clinical data as of September 25, 2025, the preliminary data cutoff from its ongoing phase 2 clinical trial investigating FID-007 in combination with cetuximab in ≤ 2nd line treatment of patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).AI SummaryFulgent Genetics announced preliminary data as of September 25, 2025, from its phase 2 study of FID-007 plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. The results will be shared October 20 at the ESMO Congress in Berlin. Of 39 randomized patients (36 treated), the objective response rate was 44% at 75 mg/m2 and 59% at 125 mg/m2, for an overall 51%. Median progression-free survival was 9.2 months and 7.8 months in the two arms, compared to a 2.3-month historical benchmark. Safety was acceptable, with a 6% serious adverse event rate. Grade 3 or higher side effects included decreased blood counts, anemia, rash and pneumonia. No grade 3 or higher peripheral neuropathy was seen. An optimal dose will be selected after further data analysis to guide the next steps in development.Read Announcement Fulgent Genetics FDA Events - Frequently Asked Questions Has Fulgent Genetics received FDA approval? As of now, Fulgent Genetics (FLGT) has not received any FDA approvals for its therapy in the last two years. What drugs has Fulgent Genetics submitted to the FDA? In the past two years, Fulgent Genetics (FLGT) has reported FDA regulatory activity for FID-007. What is the most recent FDA event for Fulgent Genetics? The most recent FDA-related event for Fulgent Genetics occurred on May 21, 2026, involving FID-007. The update was categorized as "Abstract," with the company reporting: "Fulgent Genetics, Inc announced that its full abstract has been released on the ASCO 2026 website." What conditions do Fulgent Genetics' current drugs treat? Currently, Fulgent Genetics has one therapy (FID-007) targeting the following condition: 2nd line treatment of patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events AgomAb Therapeutics FDA EventsAmylyx Pharmaceuticals FDA EventsCoherus Oncology FDA EventsDiaMedica Therapeutics FDA EventsEntera Bio FDA EventsGalectin Therapeutics FDA EventsGilead Sciences FDA EventsJaguar Animal Health FDA EventsKalaris Therapeutics FDA EventsMicrobot Medical FDA EventsPhathom Pharmaceuticals FDA EventsQuoin Pharmaceuticals FDA EventsSilexion Therapeutics FDA EventsAbbVie FDA EventsTeleflex FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Viridian Therapeutics FDA Events CareDx FDA Events Personalis FDA Events Castle Biosciences FDA Events Burning Rock Biotech FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:FLGT last updated on 5/22/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTop Banks Warn: A Strange Day is Coming to AmericaGoldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...TradeSmith | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | SponsoredElon Musk, Larry Fink & Brian Armstrong are ALL Piling into ThisElon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...Brownstone Research | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulgent Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulgent Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Abstract - May 21,2026Abstract Drug: FID-007Announced Date: May 21, 2026Indication: 2nd line treatment of patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).AnnouncementFulgent Genetics, Inc announced that its full abstract has been released on the ASCO 2026 website.AI SummaryFulgent Genetics, Inc. said its full abstract is now available on the ASCO 2026 website. The release gives investors and researchers a closer look at the company’s latest oncology-related findings. The abstract highlights key observations from the study, showing the main results and early data that Fulgent wants to share with the medical community. This update matters because ASCO is one of the most important cancer research meetings in the world. Having the full abstract posted online allows doctors, scientists, and investors to review the details ahead of the conference. Fulgent said the information reflects its ongoing work in precision medicine and cancer testing, and it may help guide future research and product development. The company also included standard forward-looking statement language and investor contact information in the announcement.Read Announcement
Preclinical Data - October 20,2025Preclinical Data Drug: FID-007Announced Date: October 20, 2025Indication: 2nd line treatment of patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).AnnouncementFulgent Genetics, Inc. announced preliminary clinical data as of September 25, 2025, the preliminary data cutoff from its ongoing phase 2 clinical trial investigating FID-007 in combination with cetuximab in ≤ 2nd line treatment of patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).AI SummaryFulgent Genetics announced preliminary data as of September 25, 2025, from its phase 2 study of FID-007 plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. The results will be shared October 20 at the ESMO Congress in Berlin. Of 39 randomized patients (36 treated), the objective response rate was 44% at 75 mg/m2 and 59% at 125 mg/m2, for an overall 51%. Median progression-free survival was 9.2 months and 7.8 months in the two arms, compared to a 2.3-month historical benchmark. Safety was acceptable, with a 6% serious adverse event rate. Grade 3 or higher side effects included decreased blood counts, anemia, rash and pneumonia. No grade 3 or higher peripheral neuropathy was seen. An optimal dose will be selected after further data analysis to guide the next steps in development.Read Announcement
